CovidStanfordV1, Main, Exploration, bibRecord, 000123

Specific Considerations for Venovenous Extracorporeal Membrane Oxygenation During Coronavirus Disease 2019 Pandemic.

Identifieur interne : 000123 ( Main/Exploration ); précédent : 000122; suivant : 000124

Specific Considerations for Venovenous Extracorporeal Membrane Oxygenation During Coronavirus Disease 2019 Pandemic.

Auteurs : Julien Guihaire [France] ; Clark G. Owyang [États-Unis] ; Jai Madhok [États-Unis] ; Florent Laverdure [France] ; Maïra Gaillard [France] ; Antoine Girault [France] ; Guillaume Lebreton [France] ; Olaf Mercier [France]

Source :

ASAIO journal (American Society for Artificial Internal Organs : 1992) [ 1538-943X ]

RBID : pubmed:33136589

Descripteurs français

KwdFr :
- Adulte d'âge moyen (MeSH), Anticoagulants (usage thérapeutique), Betacoronavirus (MeSH), Femelle (MeSH), Humains (MeSH), Héparine (usage thérapeutique), Infections à coronavirus (complications), Infections à coronavirus (thérapie), Mâle (MeSH), Oxygénation extracorporelle sur oxygénateur à membrane (effets indésirables), Oxygénation extracorporelle sur oxygénateur à membrane (méthodes), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (thérapie), Thrombose (prévention et contrôle), Thrombose (étiologie).
MESH :
- effets indésirables : Infections à coronavirus, Oxygénation extracorporelle sur oxygénateur à membrane, Pneumopathie virale.
- méthodes : Oxygénation extracorporelle sur oxygénateur à membrane.
- prévention et contrôle : Thrombose.
- thérapie : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Anticoagulants, Héparine.
- étiologie : Thrombose.
- Adulte d'âge moyen, Betacoronavirus, Femelle, Humains, Mâle, Pandémies.

English descriptors

KwdEn :
- Anticoagulants (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (complications), Coronavirus Infections (therapy), Extracorporeal Membrane Oxygenation (adverse effects), Extracorporeal Membrane Oxygenation (methods), Female (MeSH), Heparin (therapeutic use), Humans (MeSH), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (therapy), Respiratory Distress Syndrome (virology), SARS-CoV-2 (MeSH), Thrombosis (etiology), Thrombosis (prevention & control).
MESH :
- chemical , therapeutic use : Anticoagulants, Heparin.
- adverse effects : Extracorporeal Membrane Oxygenation.
- complications : Coronavirus Infections, Pneumonia, Viral.
- etiology : Thrombosis.
- methods : Extracorporeal Membrane Oxygenation.
- prevention & control : Thrombosis.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Respiratory Distress Syndrome.
- Betacoronavirus, COVID-19, Female, Humans, Male, Middle Aged, Pandemics, SARS-CoV-2.

Abstract

Extracorporeal membrane oxygenation (ECMO) is recognized as organ support for potentially reversible acute respiratory distress syndrome (ARDS). However, limited resource during the outbreak and the coagulopathy associated with coronavirus disease 2019 (COVID-19) make the utilization of venovenous (VV) ECMO highly challenging. We herein report specific considerations for cannulation configurations and ECMO management during the pandemic. High blood flow and anticoagulation at higher levels than usual practice for VV ECMO may be required because of thrombotic hematologic profile of COVID-19. Among our first 24 cases (48.8 ± 8.9 years), 17 patients were weaned from ECMO after a mean duration of 19.0 ± 10.1 days and 16 of them have been discharged from ICU.

DOI: 10.1097/MAT.0000000000001251
PubMed: 33136589

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000200
to stream Main, to step Curation: 000200

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Specific Considerations for Venovenous Extracorporeal Membrane Oxygenation During Coronavirus Disease 2019 Pandemic.</title>
<author><name sortKey="Guihaire, Julien" sort="Guihaire, Julien" uniqKey="Guihaire J" first="Julien" last="Guihaire">Julien Guihaire</name>
<affiliation wicri:level="3"><nlm:affiliation>From the Department of Cardiac Surgery, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>From the Department of Cardiac Surgery, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Paris-Saclay University School of Medicine, Le Kremlin-Bicêtre, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris-Saclay University School of Medicine, Le Kremlin-Bicêtre</wicri:regionArea>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Owyang, Clark G" sort="Owyang, Clark G" uniqKey="Owyang C" first="Clark G" last="Owyang">Clark G. Owyang</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Medicine, Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Madhok, Jai" sort="Madhok, Jai" uniqKey="Madhok J" first="Jai" last="Madhok">Jai Madhok</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Anesthesiology, Pain, and Perioperative Medicine, Division of Critical Care Medicine, Stanford University School of Medicine, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Anesthesiology, Pain, and Perioperative Medicine, Division of Critical Care Medicine, Stanford University School of Medicine</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Laverdure, Florent" sort="Laverdure, Florent" uniqKey="Laverdure F" first="Florent" last="Laverdure">Florent Laverdure</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gaillard, Maira" sort="Gaillard, Maira" uniqKey="Gaillard M" first="Maïra" last="Gaillard">Maïra Gaillard</name>
<affiliation wicri:level="3"><nlm:affiliation>From the Department of Cardiac Surgery, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>From the Department of Cardiac Surgery, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Girault, Antoine" sort="Girault, Antoine" uniqKey="Girault A" first="Antoine" last="Girault">Antoine Girault</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lebreton, Guillaume" sort="Lebreton, Guillaume" uniqKey="Lebreton G" first="Guillaume" last="Lebreton">Guillaume Lebreton</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié-Salpêtrière Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne University Medical School, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié-Salpêtrière Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne University Medical School, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>INSERM, UMRS 1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMRS 1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mercier, Olaf" sort="Mercier, Olaf" uniqKey="Mercier O" first="Olaf" last="Mercier">Olaf Mercier</name>
<affiliation wicri:level="1"><nlm:affiliation>Paris-Saclay University School of Medicine, Le Kremlin-Bicêtre, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris-Saclay University School of Medicine, Le Kremlin-Bicêtre</wicri:regionArea>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020 Nov/Dec</date>
<idno type="RBID">pubmed:33136589</idno>
<idno type="pmid">33136589</idno>
<idno type="doi">10.1097/MAT.0000000000001251</idno>
<idno type="wicri:Area/Main/Corpus">000200</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000200</idno>
<idno type="wicri:Area/Main/Curation">000200</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000200</idno>
<idno type="wicri:Area/Main/Exploration">000200</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Specific Considerations for Venovenous Extracorporeal Membrane Oxygenation During Coronavirus Disease 2019 Pandemic.</title>
<author><name sortKey="Guihaire, Julien" sort="Guihaire, Julien" uniqKey="Guihaire J" first="Julien" last="Guihaire">Julien Guihaire</name>
<affiliation wicri:level="3"><nlm:affiliation>From the Department of Cardiac Surgery, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>From the Department of Cardiac Surgery, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Paris-Saclay University School of Medicine, Le Kremlin-Bicêtre, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris-Saclay University School of Medicine, Le Kremlin-Bicêtre</wicri:regionArea>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Owyang, Clark G" sort="Owyang, Clark G" uniqKey="Owyang C" first="Clark G" last="Owyang">Clark G. Owyang</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Medicine, Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Madhok, Jai" sort="Madhok, Jai" uniqKey="Madhok J" first="Jai" last="Madhok">Jai Madhok</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Anesthesiology, Pain, and Perioperative Medicine, Division of Critical Care Medicine, Stanford University School of Medicine, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Anesthesiology, Pain, and Perioperative Medicine, Division of Critical Care Medicine, Stanford University School of Medicine</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Laverdure, Florent" sort="Laverdure, Florent" uniqKey="Laverdure F" first="Florent" last="Laverdure">Florent Laverdure</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gaillard, Maira" sort="Gaillard, Maira" uniqKey="Gaillard M" first="Maïra" last="Gaillard">Maïra Gaillard</name>
<affiliation wicri:level="3"><nlm:affiliation>From the Department of Cardiac Surgery, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>From the Department of Cardiac Surgery, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Girault, Antoine" sort="Girault, Antoine" uniqKey="Girault A" first="Antoine" last="Girault">Antoine Girault</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lebreton, Guillaume" sort="Lebreton, Guillaume" uniqKey="Lebreton G" first="Guillaume" last="Lebreton">Guillaume Lebreton</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié-Salpêtrière Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne University Medical School, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié-Salpêtrière Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne University Medical School, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>INSERM, UMRS 1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, UMRS 1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mercier, Olaf" sort="Mercier, Olaf" uniqKey="Mercier O" first="Olaf" last="Mercier">Olaf Mercier</name>
<affiliation wicri:level="1"><nlm:affiliation>Paris-Saclay University School of Medicine, Le Kremlin-Bicêtre, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris-Saclay University School of Medicine, Le Kremlin-Bicêtre</wicri:regionArea>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
<wicri:noRegion>Le Kremlin-Bicêtre</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">ASAIO journal (American Society for Artificial Internal Organs : 1992)</title>
<idno type="eISSN">1538-943X</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticoagulants (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Extracorporeal Membrane Oxygenation (adverse effects)</term>
<term>Extracorporeal Membrane Oxygenation (methods)</term>
<term>Female (MeSH)</term>
<term>Heparin (therapeutic use)</term>
<term>Humans (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>Respiratory Distress Syndrome (virology)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Thrombosis (etiology)</term>
<term>Thrombosis (prevention & control)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term>
<term>Anticoagulants (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Héparine (usage thérapeutique)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (thérapie)</term>
<term>Mâle (MeSH)</term>
<term>Oxygénation extracorporelle sur oxygénateur à membrane (effets indésirables)</term>
<term>Oxygénation extracorporelle sur oxygénateur à membrane (méthodes)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (thérapie)</term>
<term>Thrombose (prévention et contrôle)</term>
<term>Thrombose (étiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticoagulants</term>
<term>Heparin</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Extracorporeal Membrane Oxygenation</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Oxygénation extracorporelle sur oxygénateur à membrane</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Thrombosis</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Extracorporeal Membrane Oxygenation</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Oxygénation extracorporelle sur oxygénateur à membrane</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Thrombosis</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Thrombose</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticoagulants</term>
<term>Héparine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Respiratory Distress Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Thrombose</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pandemics</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Betacoronavirus</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Extracorporeal membrane oxygenation (ECMO) is recognized as organ support for potentially reversible acute respiratory distress syndrome (ARDS). However, limited resource during the outbreak and the coagulopathy associated with coronavirus disease 2019 (COVID-19) make the utilization of venovenous (VV) ECMO highly challenging. We herein report specific considerations for cannulation configurations and ECMO management during the pandemic. High blood flow and anticoagulation at higher levels than usual practice for VV ECMO may be required because of thrombotic hematologic profile of COVID-19. Among our first 24 cases (48.8 ± 8.9 years), 17 patients were weaned from ECMO after a mean duration of 19.0 ± 10.1 days and 16 of them have been discharged from ICU.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">33136589</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-943X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>66</Volume>
<Issue>10</Issue>
<PubDate><MedlineDate>2020 Nov/Dec</MedlineDate>
</PubDate>
</JournalIssue>
<Title>ASAIO journal (American Society for Artificial Internal Organs : 1992)</Title>
<ISOAbbreviation>ASAIO J</ISOAbbreviation>
</Journal>
<ArticleTitle>Specific Considerations for Venovenous Extracorporeal Membrane Oxygenation During Coronavirus Disease 2019 Pandemic.</ArticleTitle>
<Pagination><MedlinePgn>1069-1072</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/MAT.0000000000001251</ELocationID>
<Abstract><AbstractText>Extracorporeal membrane oxygenation (ECMO) is recognized as organ support for potentially reversible acute respiratory distress syndrome (ARDS). However, limited resource during the outbreak and the coagulopathy associated with coronavirus disease 2019 (COVID-19) make the utilization of venovenous (VV) ECMO highly challenging. We herein report specific considerations for cannulation configurations and ECMO management during the pandemic. High blood flow and anticoagulation at higher levels than usual practice for VV ECMO may be required because of thrombotic hematologic profile of COVID-19. Among our first 24 cases (48.8 ± 8.9 years), 17 patients were weaned from ECMO after a mean duration of 19.0 ± 10.1 days and 16 of them have been discharged from ICU.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guihaire</LastName>
<ForeName>Julien</ForeName>
<Initials>J</Initials>
<Identifier Source="ORCID">0000-0001-7414-3176</Identifier>
<AffiliationInfo><Affiliation>From the Department of Cardiac Surgery, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Paris-Saclay University School of Medicine, Le Kremlin-Bicêtre, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Owyang</LastName>
<ForeName>Clark G</ForeName>
<Initials>CG</Initials>
<Identifier Source="ORCID">0000-0001-9435-2944</Identifier>
<AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Madhok</LastName>
<ForeName>Jai</ForeName>
<Initials>J</Initials>
<Identifier Source="ORCID">0000-0002-3567-4465</Identifier>
<AffiliationInfo><Affiliation>Department of Anesthesiology, Pain, and Perioperative Medicine, Division of Critical Care Medicine, Stanford University School of Medicine, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Laverdure</LastName>
<ForeName>Florent</ForeName>
<Initials>F</Initials>
<Identifier Source="ORCID">0000-0002-6969-363</Identifier>
<AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gaillard</LastName>
<ForeName>Maïra</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>From the Department of Cardiac Surgery, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Girault</LastName>
<ForeName>Antoine</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lebreton</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Cardiac and Thoracic Surgery, Cardiology Institute, Pitié-Salpêtrière Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne University Medical School, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>INSERM, UMRS 1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mercier</LastName>
<ForeName>Olaf</ForeName>
<Initials>O</Initials>
<Identifier Source="ORCID">0000-0002-4760-6267</Identifier>
<AffiliationInfo><Affiliation>Paris-Saclay University School of Medicine, Le Kremlin-Bicêtre, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Pulmonary Hypertension National Referral Center, Le Plessis Robinson, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>ASAIO J</MedlineTA>
<NlmUniqueID>9204109</NlmUniqueID>
<ISSNLinking>1058-2916</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9005-49-6</RegistryNumber>
<NameOfSubstance UI="D006493">Heparin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>11</Month>
<Day>2</Day>
<Hour>17</Hour>
<Minute>11</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>11</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33136589</ArticleId>
<ArticleId IdType="doi">10.1097/MAT.0000000000001251</ArticleId>
<ArticleId IdType="pii">00002480-202011000-00001</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Shekar K, Badulak J, Peek G, et al.: Extracorporeal Life Support Organization COVID-19 interim guidelines. ASAIO J. 2020.66:707–721</Citation>
</Reference>
<Reference><Citation>World Health Organization: Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected: Interim Guidance, 13 March 2020. 2020.Geneva: World Health Organization;</Citation>
</Reference>
<Reference><Citation>Alhazzani W, Møller MH, Arabi YM, et al.: Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19) Intensive Care Med. 2020.46:854–887.</Citation>
</Reference>
<Reference><Citation>Li X, Guo Z, Li B, et al.: Extracorporeal membrane oxygenation for coronavirus disease 2019 in Shanghai, China. ASAIO J. 2020.66:475–481.</Citation>
</Reference>
<Reference><Citation>Schmidt M, Pham T, Arcadipane A, et al.: Mechanical ventilation management during extracorporeal membrane oxygenation for acute respiratory distress syndrome. An international multicenter prospective cohort. Am J Respir Crit Care Med. 2019.200:1002–1012.</Citation>
</Reference>
<Reference><Citation>Schmidt M, Tachon G, Devilliers C, et al.: Blood oxygenation and decarboxylation determinants during venovenous ECMO for respiratory failure in adults. Intensive Care Med. 2013.39:838–846.</Citation>
</Reference>
<Reference><Citation>Tang N, Li D, Wang X, Sun Z: Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020.18:844–847.</Citation>
</Reference>
<Reference><Citation>Sidebotham D, Allen SJ, McGeorge A, Ibbott N, Willcox T: Venovenous extracorporeal membrane oxygenation in adults: Practical aspects of circuits, cannulae, and procedures. J Cardiothorac Vasc Anesth. 2012.26:893–909.</Citation>
</Reference>
<Reference><Citation>Klok FA, Kruip M, van der Meer NJM, et al.: Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Thromb Res. 2020.191:1148–1150.</Citation>
</Reference>
<Reference><Citation>Wichmann D, Sperhake JP, Lütgehetmann M, et al.: Autopsy findings and venous thromboembolism in patients with COVID-19 Ann Intern Med. 2020 [M20-2003, Epub ahead of print]</Citation>
</Reference>
<Reference><Citation>Lax SF, Skok K, Zechner P, et al.: Pulmonary arterial thrombosis in COVID-19 with fatal outcome: Results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020 [M20-2566, Epub ahead of print]</Citation>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>État de New York</li>
<li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Guihaire, Julien" sort="Guihaire, Julien" uniqKey="Guihaire J" first="Julien" last="Guihaire">Julien Guihaire</name>
</region>
<name sortKey="Gaillard, Maira" sort="Gaillard, Maira" uniqKey="Gaillard M" first="Maïra" last="Gaillard">Maïra Gaillard</name>
<name sortKey="Girault, Antoine" sort="Girault, Antoine" uniqKey="Girault A" first="Antoine" last="Girault">Antoine Girault</name>
<name sortKey="Guihaire, Julien" sort="Guihaire, Julien" uniqKey="Guihaire J" first="Julien" last="Guihaire">Julien Guihaire</name>
<name sortKey="Guihaire, Julien" sort="Guihaire, Julien" uniqKey="Guihaire J" first="Julien" last="Guihaire">Julien Guihaire</name>
<name sortKey="Laverdure, Florent" sort="Laverdure, Florent" uniqKey="Laverdure F" first="Florent" last="Laverdure">Florent Laverdure</name>
<name sortKey="Lebreton, Guillaume" sort="Lebreton, Guillaume" uniqKey="Lebreton G" first="Guillaume" last="Lebreton">Guillaume Lebreton</name>
<name sortKey="Lebreton, Guillaume" sort="Lebreton, Guillaume" uniqKey="Lebreton G" first="Guillaume" last="Lebreton">Guillaume Lebreton</name>
<name sortKey="Mercier, Olaf" sort="Mercier, Olaf" uniqKey="Mercier O" first="Olaf" last="Mercier">Olaf Mercier</name>
<name sortKey="Mercier, Olaf" sort="Mercier, Olaf" uniqKey="Mercier O" first="Olaf" last="Mercier">Olaf Mercier</name>
<name sortKey="Mercier, Olaf" sort="Mercier, Olaf" uniqKey="Mercier O" first="Olaf" last="Mercier">Olaf Mercier</name>
</country>
<country name="États-Unis"><region name="État de New York"><name sortKey="Owyang, Clark G" sort="Owyang, Clark G" uniqKey="Owyang C" first="Clark G" last="Owyang">Clark G. Owyang</name>
</region>
<name sortKey="Madhok, Jai" sort="Madhok, Jai" uniqKey="Madhok J" first="Jai" last="Madhok">Jai Madhok</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000123 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000123 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidStanfordV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33136589
   |texte=   Specific Considerations for Venovenous Extracorporeal Membrane Oxygenation During Coronavirus Disease 2019 Pandemic.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33136589" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidStanfordV1

This area was generated with Dilib version V0.6.38.
Data generation: Tue Feb 2 21:24:25 2021. Site generation: Tue Feb 2 21:26:08 2021

	Serveur d'exploration sur le Covid à Stanford
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le Covid à Stanford

Specific Considerations for Venovenous Extracorporeal Membrane Oxygenation During Coronavirus Disease 2019 Pandemic.

Specific Considerations for Venovenous Extracorporeal Membrane Oxygenation During Coronavirus Disease 2019 Pandemic.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki